Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Sienna Biopharmaceuticals Inc (SNNA) USD0.0001

Sell:$0.23 Buy:$0.24 Change: $0.0273 (13.34%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.0273 (13.34%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.0273 (13.34%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing multi-asset pipeline of topical therapies that enhance the health, appearance of life of dermatology patients. It also advancing multiple product candidates derived from Topical by Design platform, all of which are designed to be suitable for chronic administration in patients with inflammatory skin diseases and other dermatologic and aesthetic conditions. It's SNA-120 is a first-in-class inhibitor of Tropomyosin receptor kinase A, or TrkA, in Phase IIb clinical development for the treatment of pruritus, or itch, associated with psoriasis, as well as for psoriasis itself. It's SNA-125 is a topical Janus kinase 3 (JAK3)/TrkA inhibitor with the potential to treat various inflammatory conditions, including atopic dermatitis, psoriasis and pruritus. Nonclinical studies have demonstrated anti-inflammatory activity in an animal model, and a favorable safety profile.

Contact details

30699 Russell Ranch Rd Ste 140
United States
+1 (818) 6292256

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$6.33 million
Shares in issue:
30.91 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Keith Leonard
    Chairman of the Board
  • Frederick Beddingfield
    President, Chief Executive Officer, Director
  • Alexander Azoy
    Chief Financial Officer
  • Sean Andrews
    Vice President, Investor Relations

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.